Was it a whim that Oncosec took a subset of patients and administered the PD-1 after monotherapy treatment? I don't recall any information being released about taking patients from the long-term monotherapy trial and doing a teaser run before the combo trial data release. If they actually did screen this subset of patients with the Biomarker test and they were non-responders that would be stronger validation for the combo trial data to come out this fall. Even though it was not a requirement for the monotherapy trial I wonder if Oncosec did screen this subset of patients with the Biomarker test and didn't release that information. Just curious if there is some crucial missing information in all this.
News 
Market Data 
Discover 
